An Open-Label Study of N-Acetyl Cysteine in Autism
The purpose of the study is to test the tolerability and efficacy of N-Acetyl Cysteine (NAC) in children with Autism.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : N-Acetyl Cysteine
Phase: Phase 2
Ages Eligible For Study:
Subjects will be eligible for this study if they participated in the Double-blind, randomized, placebo controlled study of N-Acetyl Cysteine in Autism study at Stanford University and meet all of the following criteria: 1. Outpatients between 3.0 and 12.11 years of age inclusive 2. Males and females who are physically healthy 3. diagnosis of autism based DSM-IV- TR criteria, the Autism Diagnostic Interview-Revised, and expert clinical evaluation 4. CGI Severity rating of 4 5. Care provider who can reliably bring subject to clinic visits, can provide trustworthy ratings, and interacts with subject on a regular basis 6. Ability of subject to swallow the compound 7. Stable concomitant medications for at least 2 weeks 8. No planned changes in psychosocial interventions during the open-label NAC trial